Furthermore, the limited beneficial effects of HAART towards secondary lesions might also be due to damage at the molecular level that may have occurred in the host epithelium during HIV infection and/or infections prior to initiating HAART, that possibly allows the comorbid infection to initiate and persist despite CD4-cell count improvement following initiation of therapy. The gene discussed is CD4; the disease is infection.